Sign inJoin waitlistJoin the waitlist

John Henegan

Associate Director of Clinical Research · University of Mississippi School of Medicine

Credentials: · · · ·

History

University of Mississippi School of Medicine
Present
University of Mississippi School of Medicine
Present
University of Mississippi School of Medicine
Present

Research

Heritable Cancer Syndromes Related to the Hypoxia Pathway
Review · Frontiers in Oncology · 2016 · First of 2 authors · 16 citations
Clinicopathologic Diagnostic Approach to Aggressive Variant Prostate Cancer
Review · Archives of Pathology & Laboratory Medicine · 2020 · 13 citations
Metastatic renal cell carcinoma imaging evaluation in the era of anti-angiogenic therapies
Review · Abdominal Radiology · 2016 · 9 citations

Candace Howard
2 papers
EH
Elisabeth Heath
2 papers
John Ligon
2 papers
Reza Sirous
2 papers
Srinivasan Vijayakumar
2 papers
Vani Vijayakumar
2 papers
Varsha Manucha
2 papers
Ajit Goenka
1 paper · 1 as a fellow
AF
Amy Farkas
1 paper · 1 as a fellow
Anson Thaggard
1 paper
AS
Atul Shinagare
1 paper
Brian Allen
1 paper

Clinical trials

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Site PI · Recruiting · Phase 3
Canadian Cancer Trials Group
2025–2031
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2024–2034